RSV Vaccine Market Size, Share, and Industry Analysis By Type (Recombinant/ Conjugate/ Subunit, mRNA, and Others), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

The global RSV vaccine market is witnessing significant growth. This is owing to the increasing incidence of RSV and rising patient visits to the hospital. The limited availability of drugs for preventing and treating RSV has shifted the focus of health authorities to recommend vaccination for preventing the outbreak of the disease. Such scenarios propel the growth of the market.

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV spreads through contact with respiratory droplets from an infected person or touching the surfaces contaminated with the virus and then touching your eyes, nose, or mouth. Infants and older adults are more likely to develop RSV and it causes more severe symptoms such as bronchiolitis and pneumonia. RSV can be serious and can lead to severe illness among both children and certain adults.

For instance, in June 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported around 2.1 million outpatient visits among children younger than five years old for RSV. In addition, to prevent the outbreak of the disease, the CDC updated the recommendation for RSV vaccines in adults for the 2024-2025 respiratory season. Such scenarios boosted the industry growth.

Additionally, the rising research and development initiatives by key players to receive regulatory approval for the RSV vaccine to launch it for commercial use are driving the growth of the market.

RSV Vaccine Market Driver

Initiation of Vaccination Programs to Drive Market Growth

Increasing cases of RSV during a respiratory season that peaks in winter and leads to more serious health conditions such as pneumonia, congestive heart failure, and bronchiolitis is driving the development of vaccination programs. Moreover, the limited availability of drugs for the treatment of RSV has focused on vaccination programs to protect the most vulnerable population and help ease pressures on the health service. Additionally, the rising approval for the initiation of the RSV vaccination program by healthcare committees of different countries is expected to drive the growth of the market.

• For instance, in July 2024, the Department of Health and Social Care, U.K., announced the initiation of a new vaccination program against RSV with an aim to protect newborns and older adults against RSV and its complications. The program aimed to offer the same vaccine to protect both infants and older adults from RSV and ease winter pressures on the National Health Services (NHS). In addition, starting in September 2024, the vaccination program would be started for pregnant women over 28 weeks to help protect their newborn babies.

Request a Free sample to learn more about this report.

According to data published by the National Center for Immunization & Respiratory Diseases in March 2023, the burden of RSV in adults aged 65 and more was recorded. It was found that 1.4 million adults in the U.S. visited the hospital for RSV infection treatment, and among that, 0.16 million were hospitalized every year.

RSV Vaccine Market Restraint

Side Effects Associated with RSV Vaccines May Hamper Market Growth

Despite the increasing demand for RSV vaccines to prevent severe respiratory infections, concerns about potential side effects can lead to hesitancy among healthcare providers and the public.

• According to the report published by the University of Michigan on the Economic Analysis of RSV Vaccination in adults 50 years and older, an analysis was done on the RSV vaccines provided by GSK plc. and Pfizer Inc., during May-October 2023. It was noted that around 6.0-10.0% of the individuals had severe injection site reaction or systemic reaction. Additionally, the risk of Guillain Barre syndrome (GBS) was registered after vaccine administration. Around 16 GBS cases per 1.0 million doses due to the vaccines administered by Pfizer and 3 GBS cases per 1.0 million due to the doses administered by GSK plc. were registered by the FDA. Such life-threatening adverse events associated with vaccines may hamper the growth of the market.

RSV Vaccine Market Opportunity

Increase in R&D Efforts of Pharma Companies to Strengthen Industry Expansion

As RSV is a leading cause of respiratory illness, particularly in infants, young children, and the elderly, there is a strong demand for effective vaccines. Thus, a number of biotech and pharmaceutical companies are intensifying their research and development efforts, leading to a surge in clinical trials and vaccine candidates. The increasing initiatives from pharma companies to bolster their vaccine pipeline to fulfill the rising demand for vaccines is expected to propel the industry growth during the forecast period.

• For instance, in August 2023, Meissa Vaccines, Inc. announced positive results on safety and immunogenicity data for Meissa’s intranasal live attenuated RSV vaccine candidate MV-012-968. It is a needle-free, adjuvant-free vaccine to protect infants and toddlers from respiratory syncytial virus (RSV).

Such clinical studies are expected to propel the growth of the market during 2024-2032.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Respiratory Syncytial Virus (RSV), By Key Countries/Regions, 2023


• Overview: Reimbursement & Regulatory Scenario, By Key Countries/ Region


• Overview of RSV Vaccination Programs, By Key Countries/ Region


• Pipeline Analysis, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches)


• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market is segmented into recombinant/ conjugate/ subunit, mRNA, and others.

The recombinant/conjugate/subunit segment held a substantial market share. The segment growth is attributed to rising regulatory approvals and the focus of key players on launching recombinant/conjugate/subunit vaccines for RSV prevention.

• For instance, in June 2024, GSK plc announced the approval of Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) by the U.S. Food and Drug Administration (FDA) for preventing adults 50 through 59 years of age with increased risk from RSV lower respiratory tract disease. Such approvals promote the segment growth.

Analysis by Age Group

Based on age group, the market is fragmented into pediatric and adults.

The pediatric segment held a significant share of the global RSV vaccine market. The growth of the segment is attributed to the rising number of cases of RSV infections in newborns and young children. The infections in pediatric populations worsen during the respiratory season, leading to more serious effects and hospitalization. Thus, to prevent the serious effects of RSV infections in children, companies are focusing on research and development to launch vaccines for pediatric population.

• For instance, in November 2022, Meissa Vaccines, Inc. revealed interim clinical data from Phase 1c study of intranasal live attenuated RSV vaccine candidate MV-012-968 for infants and young children. It is a needle-free, adjuvant-free vaccine aimed at safeguarding infants and young children from RSV.

Such trials are expected to promote the growth of the segment.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital & retail pharmacies, government suppliers, and others.

The hospital and retail pharmacies segment held a significant market share. The growth of the segment is attributed to the presence of a majority of prescription drugs and vaccines in hospital and retail pharmacies. These distribution channels are convenient for patients and consumers. In addition, increasing collaboration activities among key players and the pharmacies to offer the RSV vaccines to the consumers is expected to propel the segment growth.

• For instance, in August 2023, GSK plc announced the availability of the AREXVY vaccine for the prevention of Respiratory Syncytial Virus in all major retail pharmacies of the U.S.

Thus, the widespread presence and ability to provide vaccines efficiently and conveniently contribute significantly to the segment growth.

Regional Analysis

To gain extensive insights into the market, Request for Customization

Based on region, the market has been studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for a substantial share of the global RSV vaccine market in 2023. The rising prevalence of RSV infection boosts the regional growth. Furthermore, the presence of advanced healthcare facilities with vaccination programs to prevent the spread of the disease is expected to boost the regional growth. Additionally, robust research and development facilities, strong expenditure, and the presence of key players in the market with rising initiatives for the development and launch of vaccines for adults, children, and pregnant women are promoting the regional expansion.

• For instance, in August 2024, U.S. Health and Human Services introduced a new national campaign to inform the public about common respiratory viruses and available vaccines. The campaign aimed to increase awareness of vaccines that reduce serious illness from influenza (flu), COVID-19, and respiratory syncytial virus (RSV) in high-risk populations and to limit the spread of these viruses among all Americans. Such programs boost the adoption of RSV vaccines in the region.

Europe has a considerable share of the RSV vaccine market. The high healthcare expenditure and the presence of active vaccination programs augment the growth of the region. Also, the presence of key companies with research and development initiatives to launch vaccines for RSV prevention is expected to boost the regional growth.

• For instance, in June 2024, Germany's influential vaccine advisory panel announced that all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect themselves against RSV. Such initiatives propel the regional growth.

Moreover, the Asia Pacific region is expected to grow during the forecast period. The growth of the region is attributed to the rising prevalence of RSV infections and chronic diseases associated with it in infants, children, and adults. In addition, the growing number of vaccination drives by government bodies is expected to propel the segment growth.

Key Players Covered

The global RSV vaccine market is consolidated, with a large number of group and standalone providers.

The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)


• GSK plc. (U.K.)


• AstraZeneca (U.K.)


• Moderna, Inc. (U.S.)


• Meissa Vaccines, Inc. (U.S.)

Key Industry Developments

• In May 2024, Moderna, Inc. announced the approval of mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine by the U.S. Food and Drug Administration (FDA). It is used to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.


• In July 2023, the U.S. Food and Drug Administration (FDA) announced the approval of AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season.


• In April 2023, Sanofi collaborated with AstraZeneca for the development and commercialization of Beyfortus (nirsevimab) in the U.S.